{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:13:16Z","timestamp":1655388796815},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,2,2]]},"DOI":"10.18632\/oncotarget.23879","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T05:58:00Z","timestamp":1515045480000},"page":"8450-8462","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015"],"prefix":"10.18632","volume":"9","author":[{"given":"Sarah","family":"Hintermair","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Zwickl-Traxler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijlh.12509","article-title":"Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic\/myeloproliferative neoplasms: current diagnostic principles and upcoming updates","volume":"38","author":"Orazi","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Vainchenker","year":"2011","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"4","first-page":"2139","article-title":"Polycythemia vera","volume":"69","author":"Viera","year":"2004","journal-title":"Am Fam Physician"},{"key":"5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Kralovics","year":"2017","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s002779900136","article-title":"Myeloproliferative disorders: complications, survival and causes of death","volume":"79","author":"Skoda","year":"2000","journal-title":"Ann Hematol"},{"key":"7","doi-asserted-by":"publisher","first-page":"52614","DOI":"10.18632\/oncotarget.10376","article-title":"CALR mutation characterization in myeloproliferative neoplasms","volume":"7","author":"Gomez-Casares","year":"2016","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Girodon","year":"2014","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Bagienski","year":"2013","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Hinton","year":"2013","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Green","year":"2017","journal-title":"Haematologica"},{"key":"12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","article-title":"Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice","volume":"90","author":"Barbui","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"13","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"124","author":"Mesa","year":"2014","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Mesa","year":"2014","journal-title":"Eur J Haematol"},{"key":"16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.12873","article-title":"Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry","volume":"98","author":"Andreasson","year":"2017","journal-title":"Eur J Haematol"},{"key":"17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group","volume":"102","author":"Pahl","year":"2017","journal-title":"Haematologica"},{"key":"18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"19","first-page":"40","article-title":"[Elevated Hemoglobin--polyglobulia or polycythemia?]. [Article in German]","volume":"149","author":"Spiekermann","year":"2007","journal-title":"MMW Fortschr Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Buske","year":"2015","journal-title":"Ann Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.18632\/oncotarget.281","article-title":"Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies","volume":"2","author":"Cazzola","year":"2011","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia","volume":"17","author":"van Vliet","year":"2006","journal-title":"Platelets"},{"key":"23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1055\/s-2006-942759","article-title":"The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","article-title":"Current and future treatment options for polycythemia vera","volume":"94","author":"Mesa","year":"2015","journal-title":"Ann Hematol"},{"key":"25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Barbui","year":"2004","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000454953","article-title":"Polycythemia Vera Management and Challenges in the Community Health Setting","volume":"92","author":"Dao","year":"2017","journal-title":"Oncology"},{"key":"28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.18632\/oncotarget.986","article-title":"Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha","volume":"4","author":"Mullaly","year":"2013","journal-title":"Oncotarget"},{"key":"29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Cazzola","year":"2017","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1080\/10428194.2017.1312371","article-title":"Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery","volume":"58","author":"Stein","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Mesa","year":"2011","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.13605","article-title":"How we diagnose and treat essential thrombocythaemia","volume":"171","author":"Harrison","year":"2015","journal-title":"Br J Haematol"},{"key":"33","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","article-title":"How I treat essential thrombocythemia","volume":"128","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Mascarenhas","year":"2016","journal-title":"Haematologica"},{"key":"35","first-page":"1179545X17695233","article-title":"Treatment of Myelofibrosis: Old and New Strategies","volume":"10","author":"Cattaneo","year":"2017","journal-title":"Clin Med Insights Blood Disord"},{"key":"36","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Schouten","year":"2012","journal-title":"Eur J Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Dores","year":"2016","journal-title":"Br J Haematol"},{"key":"38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Kreipe","year":"2012","journal-title":"Haematologica"},{"key":"39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3892\/mmr.2015.4621","article-title":"Extramedullary hematopoiesis: Elucidating the function of the hematopoietic stem cell niche (Review)","volume":"13","author":"Kurata","year":"2016","journal-title":"Mol Med Rep"},{"key":"40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Verstovsek","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Hansen","year":"2016","journal-title":"J Hematol Oncol"},{"key":"42","first-page":"1091","article-title":"Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis","volume":"8","author":"Gale","year":"2015","journal-title":"Onco Targets Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:32:31Z","timestamp":1589023951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,2,2]]}},"alternative-id":["23879","29492207"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23879","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}